Why involve Payers now?

As a new treatment moves closer to protocol finalization, early payer involvement becomes critical to shaping a compelling, credible value story. The synopsis phase is the opportunity to align study design with payer priorities—ensuring continued interest, relevance, and downstream access success.

Engaging payers at this stage helps strengthen the treatment’s value proposition by clearly articulating its clinical and economic advantages, including improvements in health outcomes, quality of life, and cost‑effectiveness. Incorporating robust comparative data—demonstrating how the treatment performs against existing options—further reinforces its differentiated value.

Payers can also provide insight into how health economic models should be structured to illustrate budget impact and long‑term cost savings, supporting informed coverage decisions. Emphasizing patient‑centered outcomes, such as patient‑reported outcomes and quality‑of‑life measures, aligns the study with evidence that increasingly influences payer decision‑making.

Finally, ensuring trial design and data collection approaches meet regulatory expectations enhances credibility, while tailoring communication to the needs and decision frameworks of different payer audiences maximizes the impact and usability of study results.